MedPath

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Phase 2
Completed
Conditions
Polycythemia Vera
Thrombocythemia
Myelofibrosis
Interventions
Registration Number
NCT04629508
Lead Sponsor
Incyte Corporation
Brief Summary

This is a 2-part study. In Part 1, participants will be dosed at 2 different dose levels in order to select the RP2D for Part 2 of the study.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
4
Inclusion Criteria
  • Diagnosis of primary MF meeting the 2016 WHO criteria for overt PMF or secondary MF (PPV-MF or PET-MF) meeting the 2008 IWG-MRT criteria.
  • At least Intermediate 1 risk MF according to the DIPSS.
  • Prior treatment with ruxolitinib and/or fedratinib monotherapy
  • Currently receiving ruxolitinib or fedratinib monotherapy for PMF or secondary MF.
  • Splenomegaly defined as palpable spleen at least 5 cm below the left costal margin or volume ≥ 450 cm3 on imaging assessed during screening.
  • Allogeneic stem cell transplant not planned.
  • Platelet is greater than or equal to 50 × 109/L at screening.
  • Ability to comprehend and willingness to sign a written ICF for the study.
  • Willingness to avoid pregnancy or fathering children.
Exclusion Criteria
  • Prior treatment with a JAK inhibitor other than ruxolitinib or fedratinib
  • Record of ≥ 10% myeloid blasts in the peripheral blood (on peripheral blood smear) or bone marrow prior to or at the time of screening
  • For participants on ruxolitinib or fedratinib, unable to be tapered from that treatment over the course of 14 days without corticosteroids, hydroxyurea, or other agents
  • Treatment with ruxolitinib, fedratinib or other MF-directed therapy (approved or investigational) within 2 weeks of Day 1
  • Prior splenectomy or splenic irradiation within 6 months before receiving the first dose of itacitinib
  • Unable or unwilling to undergo serial MRI or CT scans for spleen volume measurement
  • Unable or unwilling to complete MFSAF v4.0 diary on a daily basis during the study
  • ECOG performance status ≥ 3
  • Life expectancy less than 24 weeks
  • Not willing to receive RBC or platelet transfusions
  • Participants with laboratory values at screening outside of protocol defined ranges
  • Significant concurrent, uncontrolled medical condition
  • Participants with impaired cardiac function or clinically significant cardiac disease unless approved by medical monitor/sponsor
  • History or presence of an abnormal ECG that, in the investigator's opinion, is clinically meaningful
  • Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment.
  • Evidence of HBV or HCV infection or risk of reactivation
  • Known HIV infection.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
Part 2 : Dose Expansion of itacitinibitacitinibParticipants will be dosed at the recommended Phase 2 dose (RP2D) identified in Part 1.
Part 1 : Dose Escalation of itacitinibitacitinibParticipants will be dosed at different dose levels with a maximum of up to 9 participants per dose level.
Primary Outcome Measures
NameTimeMethod
Part 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)up to 724 days

An adverse event was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug-related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as an AE that was reported for the first time or the worsening of a pre-existing event after the first dose of study treatment.

Part 1: Number of Participants With Any Grade 3 or Higher TEAEup to 724 days

A TEAE was defined as an AE that was reported for the first time or the worsening of a pre-existing event after the first dose of study treatment. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grades 1 through 5. The investigator made an assessment of intensity for each AE and SAE reported during the study and assigned it to 1 of the following categories: Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

Part 2: Splenic Response Rate (SRR) at Week 24Baseline; Week 24

SRR was defined as the percentage of participants who had a reduction in spleen volume (by imaging) of at least 35% when compared with Baseline.

Secondary Outcome Measures
NameTimeMethod
Part 2: Number of Participants With Any TEAEup to at least 24 weeks

An adverse event was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug-related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as an AE that was reported for the first time or the worsening of a pre-existing event after the first dose of study treatment.

Part 2: Number of Participants With Any Grade 3 or Higher TEAEup to at least 24 weeks

A TEAE was defined as an AE that was reported for the first time or the worsening of a pre-existing event after the first dose of study treatment. The severity of AEs was assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Grades 1 through 5. The investigator made an assessment of intensity for each AE and SAE reported during the study and assigned it to 1 of the following categories: Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated. Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living. Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent treatment indicated. Grade 5: fatal.

Part 2: Total Symptom Score (TSS) Response Rate at Week 24Baseline; Week 24

TSS response was defined as the percentage of participants who achieved at least 50% reduction in TSS over the 28 days immediately before the end of Week 24 compared with the 7 days immediately before the initiation of itacitinib immediate release (aseline).B

Part 2: Mean Change (From Day 1 Versus Week 12 and Week 24) in the 5 Multi-item Functional Scale Scores and the Multi-item Global Health Status Scale Score (EORTC QLQ-C30)Baseline; Weeks 12 and 24

The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) was to be used to assess the improvement in quality of life.

Part 2: Percentage of Participants Categorized as Improved on the Week 24 Patient Global Impression of Change (PGIC)Baseline; Week 24

The PGIC consists of a single question pertaining to a participant's overall status since the start of the study. The questionnaire gives participants 7 options to describe their overall status including: very much improved, much improved, minimally improved, no change, minimally worse, much worse, and very much worse.

Trial Locations

Locations (21)

Treviso Hospital

🇮🇹

Treviso, Italy

Vanderbilt University

🇺🇸

Nashville, Tennessee, United States

Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele

🇮🇹

Milan, Italy

Cliniques Universitaires Ucl Saint-Luc

🇧🇪

Brussels, Belgium

Pratia Hematologia Katowice

🇵🇱

Katowice, Poland

Midamerica Cancer Care

🇺🇸

Kansas City, Missouri, United States

Texas Oncology - Baylor Sammons Cancer Center

🇺🇸

Dallas, Texas, United States

New Jersey Hematology Oncology Associates Llc

🇺🇸

Brick, New Jersey, United States

Renovatio Clinical Consultants Llc

🇺🇸

Spring, Texas, United States

Baptist Cancer Center

🇺🇸

Memphis, Tennessee, United States

Hospital Universitario 12 de Octubre

🇪🇸

Madrid, Spain

AZ DELTA

🇧🇪

Roeselare, Belgium

Universitatsklinikum Halle (Saale)

🇩🇪

Halle (saale), Germany

Chu Ucl Namur University Hospital Mont-Godinne

🇧🇪

Yvoir, Belgium

Rcca Md, Llc

🇺🇸

Bethesda, Maryland, United States

Interne 1 - Hematologie Mit Stammzelltransplantation, Hemostaseologie Und Medizinische Onkologie Ord

🇦🇹

Linz, Austria

Tulane University

🇺🇸

New Orleans, Louisiana, United States

Jessa Ziekenhuis

🇧🇪

Hasselt, Belgium

Aou San Giovanni Di Dio E Ruggi

🇮🇹

Salerno, Italy

Universitaetsmedizin Greifswald

🇩🇪

Greifswald, Germany

Hospital Universitari I Politecnic La Fe

🇪🇸

Valencia, Spain

© Copyright 2025. All Rights Reserved by MedPath